Long-term angiographic follow-up of normal and minimally diseased saphenous vein grafts

Department of Medicine, Veterans Affairs Medical Center, Buffalo, New York 14215.

OBJECTIVES. We sought to ascertain the long-term fate of saphenous vein grafts known to be angiographically normal or minimally diseased 5 years after operation. This information may prove helpful in the management of such grafts at reoperation. BACKGROUND. Patients undergoing a second coronary bypass operation frequently have one or more saphenous vein grafts that remain widely patent. It is common practice during such reoperations to replace all vein grafts that are older than 5 years, including those with little or no angiographic stenosis, because of the risk of late vein graft closure. However, the long-term behavior of these angiographically normal or minimally diseased vein grafts has not been well elucidated. METHODS. Sixty-two patients with a total of 131 angiographically normal or minimally diseased (< 35% diameter narrowing) vein graft segments studied 6.1 +/- 2.1 years (mean +/- SD) after coronary bypass operation were identified by reviewing the cardiac catheterization records of the Veterans Affairs Medical Center, Buffalo, New York. Repeat angiography was performed on these patients 5.1 +/- 1.4 years after the initial postoperative angiogram (11.0 +/- 2.0 years after operation). RESULTS. On restudy, 53% of the vein grafts remained normal or only minimally diseased, 18% showed moderate stenosis (35% to 69%), 8% were patent but with severe disease (70% to 99%) and 21% were totally occluded. Disease progression was similar in grafts that were previously normal compared with those that had minimal disease. CONCLUSIONS. The long-term patency of angiographically normal or minimally diseased vein grafts is good (79% 5-year patency rate, 71% free of severe disease). The presence of minimal disease does not adversely affect long-term patency. The recommendation to replace normal or minimally diseased vein grafts during late reoperation should be reevaluated.

This article has been cited by other articles:

				L. Liao, D. F. Kong, L. K. Shaw, M. H. Sketch Jr, C. A. Milano, K. L. Lee, and D. B. Mark A New Anatomic Score for Prognosis After Cardiac Catheterization in Patients with Previous Bypass Surgery J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1684 - 1692. [Abstract] [Full Text] [PDF]

				B. S. Donahue Factor V Leiden and Perioperative Risk Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634. [Abstract] [Full Text] [PDF]

				M. J. Domanski, C. B. Borkowf, L. Campeau, G. L. Knatterud, C. White, B. Hoogwerf, Y. Rosenberg, N. L. Geller, and the Post-CABG Trial Investigators Prognostic factors for atherosclerosis progression in saphenous vein grafts: The postcoronary artery bypass graft (post-CABG) trial J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1877 - 1883. [Abstract] [Full Text] [PDF]

				J. G. Motwani and E. J. Topol Aortocoronary Saphenous Vein Graft Disease : Pathogenesis, Predisposition, and Prevention Circulation, March 10, 1998; 97(9): 916 - 931. [Abstract] [Full Text] [PDF]

				E. A. Tovar, N. Blau, A. Borsari, D. W. Landa, and J. M. Packer Severe Deformity of a Palmaz-Schatz Stent After Normal Surgical Manipulation Ann. Thorac. Surg., January 1, 1997; 63(1): 220 - 221. [Abstract] [Full Text]

				S. M. Rajah, U. Nair, M. Rees, N. Saunders, D. Walker, G. Williams, A. Critchley, D. Beton, C. Campbell, R. A. Lawson, et al. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., April 1, 1994; 107(4): 1146 - 1153. [Abstract] [Full Text]